Press
AXIM® Biotechnologies Completes Pre-Clinical Drug Studies on New Compound Proving Tenfold Greater Inhibition of Tumor Metastasis Than Parent Compound
SAN DIEGO, March 24, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international...
AXIM® Biotechnologies Completes Acquisition of Oncology Research and Development Company Sapphire Biotech, Inc.
NEW YORK, March 18, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international...
Axim teams up with ASU to study methods to inhibit the spread of cancer
Sapphire Biotech, a facet of Axim, has partnered with ASU by providing licensing technology to support research that strives to inhibit one of the...
Partnerships & Patents: Cannabinoid-Based Medicine in Oncology
In January 2020, Sapphire Biotech, Inc., acquiree of AXIM Biotechnologies, signed an agreement with Skysong Innovations establishing license rights...
AXIM® Biotechnologies Acquiree Sapphire Biotech, Inc. Signs License Agreement to Exclusively License Patent Rights in Cancer Technology
SAN DIEGO, Jan. 22, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international...
AXIM® Biotechnologies to Acquire Leading Oncology Research and Development Company Sapphire Biotech, Inc.
SAN DIEGO, Jan. 08, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in...
Clinical Trial Begins Using Sapphire Biotech’s Lateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer
Sapphire Biotech scientists have developed a new lateral flow assay test to measure the enzyme QSOX1 that is found to be elevated in subjects with...
Sapphire Biotech Files for Small Business Investigational Research Grant to Develop Compounds That Target Metastasis
Sapphire Biotech has filed for a Small Business Investigational Research (SBIR) grant to develop potent and soluble analogs of SBI-183, a compound...
Sapphire Biotech Files for Patent Protection and Tests 200 Bladder Cancer Patient Samples to Validate its Unique Biomarker to Detect Cancer
Sapphire began testing 200 bladder cancer patient samples to test for the presence of QSOX1-related biomarkers. Utilizing Sapphire’s proprietary...
Sapphire Biotech, Inc. is Formed to Develop Novel Therapeutic Approaches for the Treatment of Cancer Metastasis
Sapphire Biotech’s technology was formed for the purpose of developing novel therapeutic approaches for the treatment of cancer metastasis. Sapphire...